Plainsboro, NJ, US and Bagsværd, Denmark, 27 May 2026 – Novo Nordisk today announced that new data from its cardiometabolic portfolio and pipeline will be showcased at the upcoming 2026 Scientific Sessions of the American Diabetes Association ® (ADA), taking place in New Orleans, June 5–8, 2026. Phase 3 REIMAGINE 1–3 results evaluating the effects of investigational CagriSema on glycemic control and weight loss across a range of type 2 diabetes background therapies will be featured in an ADA Sci

Strategic partnership combines NorthStar's commercial-scale radioisotope production capabilities with QSA Global's expertise in lifecycle management of Radium-226 (Ra-226), the starting material for Ac-225 production Agreement aims to strengthen NorthStar's no carrier added (n.c.a) Ac-225 supply chain by establishing a reliable, closed-loop source of high-purity Ra-226 target materials BURLINGTON, Mass. and BELOIT, Wis., May 27, 2026 /PRNewswire/ -- QSA Global, Inc., a global leader in specializ

New COO, CPO, and CTO bring deep healthcare AI and operations expertise as Caregentic scales its continuous care platform across health systems NEW YORK, May 27, 2026 /PRNewswire/ -- Caregentic, an AI platform that automates the operating layer of continuous care for health systems , today announced the appointment of three executives who complete its senior leadership team: Becky James as Chief Operating Officer, Matteo Carli as Chief Product Officer, and Sanjay Mahadi as Chief Technology Offic

Leading Mountain West community oncology practice adopts technology-enabled, high-touch drug management offerings that support operational efficiency, financial sustainability and long-term practice independence FRISCO, Texas and TEMPE, Ariz., May 27, 2026 /PRNewswire/ -- AllyGPO®, a leading innovator and next-generation specialty group purchasing organization (GPO), and BioCareSD®, a national specialty distributor with nearly 50 years of experience delivering high-touch specialty drug distribut

PALO ALTO, Calif.--(BUSINESS WIRE)--Signos Inc., the company behind the first FDA-cleared, over-the-counter glucose monitoring system for weight management, today announced a $20 million funding round with investment from GV (Google Ventures), Dexcom, and Blue Cross Blue Shield of Alabama. As part of the partnership with Dexcom, Signos will be available for purchase on Stelo.com, Dexcom's direct-to-consumer CGM website, making it easier for people to find and access the Signos system. Signos has

OLD BETHPAGE, N.Y. and BROOMFIELD, Colo., May 27, 2026 /PRNewswire/ -- Himed (), a pioneering producer of bioceramic materials, and Adva Cera (), a leader in advanced ceramic additive manufacturing, today announced a strategic partnership to create a complete development-to-production pathway for 3D-printed calcium phosphate (CaP) components used in dental, orthopedic, and spinal applications. Through this partnership, customers working with Himed to design and optimize additive bioceramic impla

Democratizing metabolomics for researchers worldwide, the new kit brings Metabolon's analytically rigorous, scalable metabolomics into workflows designed for integrated biological insights MORRISVILLE, N.C., May 27, 2026 /PRNewswire/ -- Metabolon, Inc., the global leader in providing metabolomics solutions advancing a wide variety of life science research, diagnostic, therapeutic development, and precision medicine applications, today announced the Metabolon Verus™ Metabolomics Profiling Kit, M

CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics Holdings, Inc. (Nasdaq: CDIO), an AI-powered precision cardiovascular medicine company, today announced that the company will exhibit at four upcoming national benefits conferences, connecting with employers, brokers, union trustees, and plan administrators on a shared challenge: cardiovascular disease (CVD). CVD remains a leading medical claims cost driver for most health plans and a major contributor to absenteeism, disability, and lost workforce pr

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced a major technological upgrade to Tempus Hub, its AI-enabled smart physician platform. Tempus is making available its advanced, next-generation generative AI clinical co-pilot directly in Hub to power an agent-first experience for healthcare providers, allowing them to integrate the benefits of large language models and generative AI capabilities

PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced that Harmony's management team will participate in the following upcoming investor conferences. Goldman Sachs 47th Annual Global Healthcare Conference Fireside Chat: June 9, 2026, at 8:40 a.m. ET Location: Miami, FL Oppenheimer CNS & Neuro-Muscular Summit Fireside Chat: June 10, 2026, at 3:25 p.m. ET Location: Miami, FL A webcast of the fireside chats will be available on the investor page